Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 15 von 32520

Details

Autor(en) / Beteiligte
Titel
Automated GMP Production and Preclinical Evaluation of [ 68 Ga]Ga-TEoS-DAZA and [ 68 Ga]Ga-TMoS-DAZA
Ist Teil von
  • Pharmaceutics, 2022-12, Vol.14 (12), p.2695
Ort / Verlag
Switzerland: MDPI AG
Erscheinungsjahr
2022
Link zum Volltext
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
  • [ Ga]Ga-TEoS-DAZA and [ Ga]Ga-TMoS-DAZA are two novel radiotracers suitable for functional PET liver imaging. Due to their specific liver uptake and biliary excretion, the tracers may be applied for segmental liver function quantification, gall tree imaging and the differential diagnosis of liver nodules. The purpose of this study was to investigate problems that occurred initially during the development of the GMP compliant synthesis procedure and to evaluate the tracers in a preclinical model. After low radiolabeling yields were attributed to precursor instability at high temperatures, an optimized radiolabeling procedure was established. Quality controls were in accordance with Ph. Eur. requirements and gave compliant results, although the method for the determination of the Ga colloid is partially inhibited due to the presence of a radioactive by-product. The determination of logP revealed [ Ga]Ga-TEoS-DAZA (ethoxy bearing) to be more lipophilic than [ Ga]Ga-TMoS-DAZA (methoxy bearing). Accordingly, biodistribution studies in an in ovo model showed a higher liver uptake for [ Ga]Ga-TEoS-DAZA. In dynamic in ovo PET imaging, rapid tracer accumulation in the liver was observed. Similarly, the activity in the intestines rose steadily within the first hour p.i., indicating biliary excretion. As [ Ga]Ga-TEoS-DAZA and [ Ga]Ga-TMoS-DAZA can be prepared according to GMP guidelines, transition into the early clinical phase is now possible.
Sprache
Englisch
Identifikatoren
ISSN: 1999-4923
eISSN: 1999-4923
DOI: 10.3390/pharmaceutics14122695
Titel-ID: cdi_doaj_primary_oai_doaj_org_article_f0890c055bbb487db0b3c60e6aa3e63d

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX